LACOSAMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H18N2O3
Molecular Weight	250.2941
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=N[C@]([H])(COC)C(=NCc1ccccc1)O)O

InChI

InChIKey=VPPJLAIAVCUEMN-GFCCVEGCSA-N

InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C13H18N2O3
Molecular Weight	250.2941
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204839s000lbl.pdf
Curator's Comment:: https://www.drugs.com/pro/lacosamide.html | http://www.wikidoc.org/index.php/Lacosamide | https://www.ncbi.nlm.nih.gov/pubmed/17461888 | https://www.ncbi.nlm.nih.gov/pubmed/19552484

Lacosamide is an anticonvulsant that is FDA approved for the treatment of partial-onset seizures. The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing Common adverse reactions include diplopia, headache, dizziness, nausea. Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to Lacosamide tablets.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Target ID: Voltage-gated sodium channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/17940193 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Blocker 504	Partial-onset seizures Diabetic neuropathy	164 µM [EC50]
Dihydropyrimidinase-related protein 2 4 Target ID: P47942 Gene ID: 25416 Gene Symbol: Dpysl2 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20538611 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Binding Agent 994
Cytochrome P450 2C19 49 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22850102	Substrate 609		1797 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Partial-onset seizures 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Primary		Approved 7997	VIMPAT Approved Use VIMPAT is indicated for: Partial-onset seizures (1.1): Tablets and oral solution are indicated for adjunctive therapy in patients ≥17 years. Injection is indicated as short term replacement when oral administration is not feasible in these patients. 1.1 Partial-Onset Seizures VIMPAT (lacosamide) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. VIMPAT (lacosamide) injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible. Launch Date 1225152000000
Diabetic neuropathy 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19552484 https://www.ncbi.nlm.nih.gov/pubmed/17237664	Palliative		Phase III 650

C_max

Value	Dose	Co-administered	Analyte	Population
2935.3 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LACOSAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
59120 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LACOSAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.47 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LACOSAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Disc. AE: Dizziness, Ataxia... AEs leading to discontinuation/dose reduction: Dizziness (>1) Ataxia (>1) Vomiting (>1) Diplopia (>1) Nausea (>1) Vertigo (>1) Vision blurred (>1) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Disc. AE: Dizziness, Ataxia... AEs leading to discontinuation/dose reduction: Dizziness (>1) Ataxia (>1) Vomiting (>1) Diplopia (>1) Nausea (>1) Vertigo (>1) Vision blurred (>1) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
600 mg 1 times / day steady, oral Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Disc. AE: Dizziness, Ataxia... AEs leading to discontinuation/dose reduction: Dizziness (>1) Ataxia (>1) Vomiting (>1) Diplopia (>1) Nausea (>1) Vertigo (>1) Vision blurred (>1) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
12 mg/kg 1 times / day multiple, oral Studied dose Dose: 12 mg/kg, 1 times / day Route: oral Route: multiple Dose: 12 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	unhealthy, ≥1 month ≤17 years Health Status: unhealthy Age Group: ≥1 month ≤17 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	Other AEs: Vomiting, Dizziness... Other AEs: Vomiting (4.8%) Dizziness (4.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/
5.82 mg/kg 1 times / day multiple, oral Dose: 5.82 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5.82 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	unhealthy, ≥1 month ≤17 years Health Status: unhealthy Age Group: ≥1 month ≤17 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/	Disc. AE: Vomiting, Gait disturbance... AEs leading to discontinuation/dose reduction: Vomiting (8.5%) Gait disturbance (6.4%) Dizziness (6.4%) Somnolence (6.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/31374487/
12 g single, oral Overdose Dose: 12 g Route: oral Route: single Dose: 12 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Other AEs: Coma... Other AEs: Coma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
1200 mg 1 times / day multiple, oral Overdose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28926353	healthy Health Status: healthy Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28926353	Other AEs: Dysarthria, Dysphemia... Other AEs: Dysarthria (severe, 1 patient) Dysphemia (severe, 1 patient) Aphasia (severe, 1 patient) Negative thoughts (severe, 1 patient) Coordination abnormal (severe, 1 patient) Muscle weakness (severe, 2 patients) Nausea (severe, 2 patients) Vomiting (severe, 2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/28926353
100 mg 2 times / day steady, oral Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	Other AEs: Myocardial infarction, Knee operation... Other AEs: Myocardial infarction (serious, 1 patient) Knee operation (serious, 1 patient) Diarrhoea (below serious, 4 patients) Fatigue (below serious, 5 patients) Nasopharyngitis (below serious, 12 patients) Bronchitis (below serious, 2 patients) Sinusitis (below serious, 4 patients) Upper respiratory tract infection (below serious, 7 patients) Dizziness (below serious, 5 patients) Oropharyngeal pain (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00440518
200 mg 2 times / day steady, oral Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00401830	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00401830	Other AEs: Vision blurred, Constipation... Other AEs: Vision blurred (below serious, 4 patients) Constipation (below serious, 5 patients) Hypoaesthesia oral (below serious, 4 patients) Nausea (below serious, 13 patients) Vomiting (below serious, 5 patients) Back pain (below serious, 4 patients) Pain in extremity (below serious, 4 patients) Balance disorder (below serious, 4 patients) Dizziness (below serious, 18 patients) Somnolence (below serious, 5 patients) Pruritus (below serious, 7 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00401830
300 mg 2 times / day steady, oral Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00440518	Other AEs: Coronary artery dissection, Vaginal infection... Other AEs: Coronary artery dissection (serious, 1 patient) Vaginal infection (serious, 1 patient) Fatigue (below serious, 11 patient) Nasopharyngitis (below serious, 11 patient) Bronchitis (below serious, 4 patients) Sinusitis (below serious, 3 patients) Oropharyngeal pain (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00440518
400 mg steady, oral Dose: 400 mg Route: oral Route: steady Dose: 400 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00485472	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00485472	Other AEs: Angina pectoris, Sick sinus syndrome... Other AEs: Angina pectoris (serious, 1 patient) Sick sinus syndrome (serious, 1 patient) Liver disorder (serious, 1 patient) Hypoglycaemic shock (serious, 1 patient) Breast cancer in situ (serious, 1 patient) Vertigo (below serious, 8 patients) Fatigue (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00485472

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1470 inducer 657 inhibitor 1172	substrate 865 inducer 343 inhibitor 1318	inhibitor 1421 substrate 1038

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1089 CYP1A1 89 CYP1A2 1268 CYP2A6 594 CYP2B6 679 CYP2C8 761 CYP2E1 761 CYP3A5 66 CYP2C19 1215	CYP2C19 830 P-gp 1223 CYP1A2 892 CYP2B6 575 CYP2C8 586	CYP1A2 618 CYP2B6 486 CYP2C19 260

Drug as perpetrator

Target	Modality	Activity
CYP1A1 188	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP1A2 1406	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no
CYP1A2 1406	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2A6 625	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2B6 845	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no
CYP2B6 845	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2C19 1277	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2C8 810	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2C9 1362	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no
CYP2C9 1362	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP2E1 841	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP3A4 1462	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no
CYP3A4 1462	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
CYP3A5 119	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	no
P-gp 1255	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 892	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	inconclusive
CYP2B6 575	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	inconclusive
CYP2C8 586	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	inconclusive
CYP2C9 865	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	inconclusive
CYP2D6 1038	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	inconclusive
CYP3A4 1470	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46	inconclusive	likely (co-administration study) Comment: POP-PK results showed that lacosamide exposure decreased 20% in the presence of carbamazepine, phenytoin, or phenobarbital Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 46
P-gp 1223	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 47	no
CYP2C19 830	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 10, 46	yes	no (co-administration study) Comment: lacosamide had no effect on omeprazole PK Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf Page: 10, 46

Sourcing

Vendor/Aggregator	ID	URL
AlchemyPharm	AP10043
Angene	AGN-PC-0O4YVA
Axon MedChem	1444
BOC Sciences	175481-26-2
Bide Pharmatech	BD159835
Cayman Chemical	10012592
Chemspace	CSC020591027
Compound Cloud	219078
Enamine	BBV-42746795
Enamine	BBV-48326204
Enamine	EN300-122357
Hangzhou APIChem Technology	AC-22750
HongKong Chemhere	SCF04159
HongKong Chemhere	SCF04163
KeyOrganics	KS-1227
Lab Seeker	SC-47701
Molnova	M12653
MuseChem	R009690
Ryan Scientific	MI-2_(MALT1_inhibitor)
ShangHai Biochempartner	BCP02197
Sigma Aldrich	L-029
Sigma Aldrich	L-029\|CERILLIAN
StruChem	SC-47701
Tetrahedron	TS01927
Toronto Research Chemicals	D296771
Toronto Research Chemicals	L098500
Wonderchem	WD02VNF
ZINC	ZINC000000007673	http://zinc15.docking.org/substances/ZINC000000007673
eMolecules	300121911
mcule	MCULE-5072423962
mcule	MCULE-8848296606

PubMed

Title	Date	PubMed
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.	2009	19816574
Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders.	2009	19552484
Gateways to clinical trials.	2009 Apr	19536362
Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.	2009 Aug	19409861
What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate.	2009 Dec	19941524
The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents.	2009 Dec 10	19818346
Clinical perspectives on lacosamide.	2009 Jan-Feb	19396339
Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care.	2009 Jun	19949568
Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.	2009 Jun	19949567
Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.	2009 Jun	19949566
Antiepileptic drug monotherapy: the initial approach in epilepsy management.	2009 Jun	19949565
Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.	2009 Jun	19454870
Lacosamide for epilepsy.	2009 Jun 29	19556941
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.	2009 Mar-Apr	19443931
Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.	2009 May 21	19507328
New drugs: Febuxostat, lacosamide, and rufinamide.	2009 May-Jun	19443330
Gateways to clinical trials.	2009 Nov	20094643
Painful diabetic neuropathy: advantage of novel drugs over old drugs?	2009 Nov	19875591
Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain.	2009 Nov	19843834
Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany.	2009 Nov	19767242
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.	2009 Nov 12	19795888
Lacosamide: new drug. Refractory partial epilepsy: optimise existing combinations.	2009 Oct	19882781
Pharmacology and treatment of neuropathic pains.	2009 Oct	19741531
Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy.	2009 Sep	19573541
Lacosamide: what can be expected from the next new antiepileptic drug?	2009 Sep-Oct	19826503
Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs.	2010 Apr	20502724
Gateways to clinical trials.	2010 Apr	20448862
Lacosamide intoxication in attempted suicide.	2010 Apr	20171144
Efficacy and safety of lacosamide in painful diabetic neuropathy.	2010 Apr	20067958
No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers.	2010 Apr	19841161
A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy.	2010 Aug	20386357
In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.	2010 Aug 13	20538611
New Drugs2010, PART 1.	2010 Feb	20083979
Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide.	2010 Feb	19674050
Drug interactions involving the new second- and third-generation antiepileptic drugs.	2010 Jan	20021326
Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property.	2010 Jan	19841906
The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors.	2010 Jan 28	20028100
Update on anticonvulsant drugs.	2010 Jul	20490745
Lacosamide: new adjunctive treatment option for partial-onset seizures.	2010 Jun	20482307
Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.	2010 Jun	20199516
Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial.	2010 Jun	20132285
Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures.	2010 Jun	20041945
Proteomic searches comparing two (R)-lacosamide affinity baits: An electrophilic arylisothiocyanate and a photoactivated arylazide group.	2010 Jun 21	20405068
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.	2010 Mar	20194146
Epileptic seizures in AD patients.	2010 Mar	19557550
[Antiepileptic drugs in North America].	2010 May	20450099
LOCF approach to handling missing data overestimates the pain score improvement of drop-outs.	2010 May	20338823
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.	2010 May 13	20394379
[The use of oral lacosamide in a patient with refractory partial epileptic status].	2010 May 16	20473836
Emerging drugs for partial onset seizures.	2010 Sep	20476851

Patents

Sample Use Guides

In Vivo Use Guide

Initially, give 50 mg twice daily (100

Route of Administration: Other

In Vitro Use Guide

In recombinant systems the effect of LCM on the potassium current mediated by the human hERG channel was studied. Inhibition of this channel has been associated with fatal arrhythmias. LCM only

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:08:55 UTC 2021` Edited by `admin` on `Fri Jun 25 21:08:55 UTC 2021`
Record UNII	563KS2PQY5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LACOSAMIDE

Official Name

English

LACOSAMIDE [EMA EPAR]

Common Name

English

LACOSAMIDE [VANDF]

Common Name

English

SPM 927

Code

English

ERLOSAMIDE

Common Name

English

LACOSAMIDE [USAN]

Common Name

English

PROPANAMIDE, 2-(ACETYLAMINO)-3-METHOXY-N-(PHENYLMETHYL)-, (2R)-

Systematic Name

English

(+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE

Systematic Name

English

LACOSAMIDE [WHO-DD]

Common Name

English

VIMPAT

Brand Name

English

LACOSAMIDE [MART.]

Common Name

English

LACOSAMIDE CV [USP-RS]

Common Name

English

LACOSAMIDE [INN]

Common Name

English

ADD 243037

Code

English

LACOSAMIDE [MI]

Common Name

English

LACOSAMIDE [EP MONOGRAPH]

Common Name

English

LACOSAMIDE [ORANGE BOOK]

Common Name

English

ADD-243037

Code

English

(R)-LACOSAMIDE 1

Common Name

English

SPM-927

Code

English

LACOSAMIDE [JAN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000008486